Did you know prostate cancer is the second-leading cause of cancer death in American men, trailing only lung cancer? However, with advancements in immunotherapy, like Dendreon's, more men are given the chance to live longer after diagnosis. In fact, over 3.3 million men in the US diagnosed with prostate cancer are still alive today. To learn more about our innovative work in immunotherapy, visit: https://loom.ly/V-g2cQ8 #ProstateCancer #Immunotherapy #DendreonPharma
Dendreon’s Post
More Relevant Posts
-
Passionate Learner , Key focus on Pharmaceutical Market , Sydney Business School, Post-MBA
Comparing Anticoagulation Strategies for Venous Thromboembolism Associated With Active Cancer: Current guidelines propose several DOACs as comparable options for VTE treatment in patients with cancer. This network meta-analysis compared DOACs and demonstrated that the antithrombotic benefit of apixaban may not result in an increased risk for bleeding events, distinguishing it from other contemporary anticoagulation strategies in patients with active cancer. Summarized by dr Hessam Kakavand
-
-
In our recent webinar, "Have You Considered Immunotherapy as an Option for Your Lung Cancer", Dr. Borghaei explains how checkpoint inhibitors treat lung cancer. Join us to learn about different types of therapies, how immunotherapy works, and how to keep track of your progress with your healthcare team. Watch now with Medlive! https://bit.ly/4brm7sh #LungCancer #Immunotherapy
-
-
Hematologist and Medical Oncologist. Epidemiologist. Biostatistician. Biotechnologist.
📣 In this first-of-its-kind study, we showed that #Immunotherapy could be used to prevent #Cancer. 🔊 We showed that Immunotherapy decreases secondary cancer by almost 70% (P<0.01). ⚡Our study has paved the way for a revolutionary approach: Preventative Immunotherapy, a promising new avenue in the battle against cancer. 🔔 Check out our abstract in the coming #ASCO24. Cleveland Clinic Merck Bristol Myers Squibb AstraZeneca Roche Jame Abraham, M.D. FACP American Society of Clinical Oncology (ASCO) #ASCO #Oncology #ClevelandClinic
-
-
READ: The FDA has approved a new chemotherapy-free combination for non-small cell lung cancer. This therapy could open doors for patients with locally advanced or metastatic NSCLC. According to Alex Spira, MD, PhD, FACP, FASCO, of Virginia Cancer Specialists, P.C., “Patients will now have the option of a potential new first-line standard of care with significant clinical benefits over osimertinib. This first-line therapy uses a targeted approach aiming to achieve the best possible patient outcomes while reserving chemotherapy for later stages of treatment when resistance becomes more complex.” Find out more here: https://lnkd.in/gr5yAq3e You can also learn more about other current cancer research here: https://lnkd.in/gDKYBipQ #CancerResearch #LungCancer #HealthcareInnovation
-
We are on track for topline data from our fully enrolled phase 3 (intermediate/high-risk; n=711) and phase 2b (low/intermediate risk, active surveillance population; n=187) randomized controlled clinical trials in early, localized prostate cancer in Q4 2024. #viral #immunotherapy #prostate #cancer #CAN-2409
It is estimated that there will be approximately 299,000 new cases of prostate cancer cases in the United States in 2024. This Prostate Cancer Awareness Month, we stand with those affected by this disease. At Candel, we're advancing our viral immunotherapy, CAN-2409, designed to empower the immune system to fight cancer, including prostate cancer, more effectively. #ProstateCancerAwareness #EndCancer
-
-
Have you ever heard the term Immunotherapy in relation to cancer treatment and wondered what it meant, exactly? Hirva Mamdani, M.D., recently talked with HealthCentral about this treatment option for non-small cell lung cancer. #YourBestChance To read more, visit https://lnkd.in/dH6WuEeb
-
UPCOMING WEBINAR - Immunotherapy Advancements: Transforming Cancer Treatment Join us as we dive into the revolutionary advancements in immunotherapy, a game-changer in cancer treatment. Key topics include: ✅ Remarkable efficacy of immunotherapy across melanoma, lung cancer, and more ✅ Overcoming resistance with innovative strategies and combination therapies ✅ Personalised treatments through precision immunotherapy ✅ Future trends, research, and challenges in the field 🌐 29 JULY 2024 at 3PM BST! Expand your knowledge and stay ahead in the fight against cancer. 💡 Register for FREE today! https://bit.ly/3ypxsK6 #Webinar #Immunotherapy #CancerResearch #HealthcareInnovation
-
-
“Sometimes a clinical trial, even as a first line of treatment, is the right approach to get you the best results. Not every doctor knows everything that is available, especially if you are in a region (where) you do not have access to a hospital that has the most up-to-date treatments," shares CRI ImmunoAdvocate and colorectal cancer survivor, Gordon. Discover how immunotherapy for colorectal cancer is changing the outlook for patients, and hear more from Gordon, and his wife, Pam, during Colorectal Cancer Awareness Month: https://bit.ly/3uYkGkC #CancerResearch #Immunotherapy #ClinicalTrial #ColorectalCancerAwareness
-
-
Explore the interaction of cancer cells with immune cells with our high-throughput co-cultures. Learn about the benefits of our advanced assays for insights on cancer immunotherapy drugs. Find out more. https://ow.ly/AgwK50Ry6Kt #immunooncology #co-cultures #drugdevelopment #drugdiscovery
-
-
Join our upcoming Special Seminar: Bioinspired protein-based cancer immunotherapy with Dr. Yanpu He to learn how immunotherapy has revolutionized the field of cancer treatment over the past two decades. https://lnkd.in/eBJJrgi3
-
